Results released Tuesday from an early study of an autoimmune disease drug from Roivant Sciences’ Immunovant showed the treatment could reduce the levels of a key immune marker in the blood, a promising signal.
The results are only from a Phase 1 trial, but were anticipated because they were the first-in-human outcomes being reported for the antibody drug, IMVT-1402. The drug is in development for a number of autoimmune diseases and is part of a burgeoning class of treatments that block a receptor known as FcRn that, when activated, can trigger such conditions. Other companies working on FcRn inhibitors include Johnson & Johnson and Argenx.
Immunovant shares saw a big jump in pre-market trading.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.